{"id":"seasonal-influenza-virus-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By introducing antigens from seasonal influenza viruses, the vaccine stimulates the body's immune system to produce antibodies and immune cells that can recognize and fight the viruses. This provides protection against seasonal influenza infections.","oneSentence":"This vaccine induces an immune response against seasonal influenza viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:50.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza disease"}]},"trialDetails":[{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT01191853","phase":"","title":"Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-18","conditions":"Healthy Volunteers, Influenza","enrollment":203},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT07340047","phase":"PHASE1","title":"H1ssF Flu Vaccine Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-08-01","conditions":"Influenza","enrollment":112},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06800885","phase":"","title":"Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-10-22","conditions":"Influenza Immunization","enrollment":5000},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT06024096","phase":"PHASE4","title":"Systems Biological Assessment of Statin Effect on Vaccine Responses","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-09-20","conditions":"Vaccine Response","enrollment":63},{"nctId":"NCT05384288","phase":"","title":"Response to Influenza Vaccination in Pediatric Oncology Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-10-07","conditions":"Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer","enrollment":150},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT07254052","phase":"","title":"Effectiveness of Ammonium Chloride in Reducing Viral Load","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-09-01","conditions":"RNA Virus Infections, Viral Infection COVID-19, Influenza A and B","enrollment":32},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT01687517","phase":"PHASE3","title":"Efficacy and Safety of Influenza Vaccine During Sarcoidosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10","conditions":"Sarcoidosis, Influenza Vaccine","enrollment":190},{"nctId":"NCT01065285","phase":"PHASE4","title":"Vaccination Against Influenza in Autoimmune Diseases","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-10","conditions":"Autoimmune Diseases","enrollment":234},{"nctId":"NCT07121192","phase":"PHASE2","title":"A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-25","conditions":"Influenza, Human","enrollment":776},{"nctId":"NCT06501963","phase":"PHASE4","title":"Revealing Protective Immunity to Influenza Using Systems Immunology","status":"COMPLETED","sponsor":"Emory University","startDate":"2024-10-14","conditions":"Influenza","enrollment":51},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT04499534","phase":"","title":"BRCA1/2 Flu Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2019-10-28","conditions":"BRCA1 Mutation, BRCA2 Mutation","enrollment":50},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT01764152","phase":"NA","title":"Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2012-12","conditions":"Adult Hospitalized","enrollment":450},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT06060457","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-25","conditions":"Respiratory Syncytial Virus","enrollment":1900},{"nctId":"NCT05823974","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-04-27","conditions":"Influenza, Human","enrollment":1275},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT05071313","phase":"PHASE3","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-10-04","conditions":"Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention","enrollment":777},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT05712759","phase":"","title":"Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2025-03-09","conditions":"Infection Viral","enrollment":""},{"nctId":"NCT05028634","phase":"PHASE3","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-11-11","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT02342249","phase":"PHASE2","title":"Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-11","conditions":"Influenza A","enrollment":292},{"nctId":"NCT03339713","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-12-07","conditions":"Healthy","enrollment":180},{"nctId":"NCT05827068","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-27","conditions":"Seasonal Influenza","enrollment":698},{"nctId":"NCT04850898","phase":"PHASE2","title":"Study of SAB-176 in Healthy Adult Participants","status":"COMPLETED","sponsor":"SAb Biotherapeutics, Inc.","startDate":"2021-06-23","conditions":"Influenza A H1N1","enrollment":62},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT06679647","phase":"NA","title":"Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-12-01","conditions":"Behavior Change Interventions","enrollment":50},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT02294487","phase":"","title":"Study of the Immune Response After Vaccination in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-12-30","conditions":"Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple","enrollment":19},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT01432340","phase":"","title":"Seasonal Influenza Vaccine Effectiveness Study in Kenya","status":"COMPLETED","sponsor":"Gideon Emukule","startDate":"2010-06","conditions":"Influenza, Influenza Like Illness, Severe Acute Respiratory Illness","enrollment":10000},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT05223179","phase":"PHASE1","title":"Intramuscular CodaVax-H1N1 in Healthy Adults","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2022-04-11","conditions":"Influenza, Human","enrollment":69},{"nctId":"NCT06294262","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"LiteVax BV","startDate":"2024-01-29","conditions":"Vaccination Reaction","enrollment":84},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT05116917","phase":"PHASE2","title":"Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2021-11-05","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT02663102","phase":"","title":"Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-20","conditions":"Influenza, Human","enrollment":1388},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05333289","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-06","conditions":"Seasonal Influenza","enrollment":572},{"nctId":"NCT05616546","phase":"PHASE4","title":"Bone Marrow and Peripheral Blood Immune Responses Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-10-16","conditions":"Influenza","enrollment":90},{"nctId":"NCT05581407","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin","status":"COMPLETED","sponsor":"LiteVax BV","startDate":"2022-10-03","conditions":"Influenza","enrollment":60},{"nctId":"NCT03688620","phase":"PHASE4","title":"Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-10-05","conditions":"Influenza, Human","enrollment":1060},{"nctId":"NCT04025580","phase":"PHASE2","title":"Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-02","conditions":"Healthy Volunteer","enrollment":98},{"nctId":"NCT02957890","phase":"PHASE4","title":"Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2016-11-18","conditions":"Influenza, Human","enrollment":400},{"nctId":"NCT03884296","phase":"PHASE4","title":"Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2019-04-15","conditions":"Influenza","enrollment":""},{"nctId":"NCT05301322","phase":"PHASE3","title":"Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-13","conditions":"Respiratory Syncytial Virus","enrollment":1471},{"nctId":"NCT04956575","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-06","conditions":"Seasonal Influenza","enrollment":885},{"nctId":"NCT02385123","phase":"PHASE4","title":"Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04-01","conditions":"Influenza, Influenza Immunisation","enrollment":60},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT05129436","phase":"","title":"Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2020-10-10","conditions":"Seasonal Influenza Vaccination","enrollment":20},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT05062759","phase":"PHASE3","title":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Moderate to Severe Asthma","enrollment":70},{"nctId":"NCT05252338","phase":"PHASE1","title":"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults","status":"COMPLETED","sponsor":"CureVac","startDate":"2022-02-07","conditions":"Influenza","enrollment":240},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT01381029","phase":"","title":"Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals","status":"COMPLETED","sponsor":"George Washington University","startDate":"2009-09","conditions":"Influenza, Human, Human Immunodeficiency Virus I Infection","enrollment":74},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Seasonal influenza virus vaccine","genericName":"Seasonal influenza virus vaccine","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response against seasonal influenza viruses. Used for Prevention of seasonal influenza disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}